U.S. prices for the world's 20 top-selling medicines are, on average, three times higher than in Britain, according to an analysis carried out for Reuters.
The finding underscores a transatlantic gulf between the price of treatments for a range of diseases and follows demands for lower drug costs in America from industry critics such as Democratic presidential candidate Hillary Clinton.
The 20 medicines, which together accounted for 15 percent of global pharmaceuticals spending in 2014, are a major source of profits for companies including AbbVie (ABBV.N), AstraZeneca (AZN.L), Merck (MRK.N), Pfizer (PFE.N) and Roche (ROG.VX).
(Score: 0) by Anonymous Coward on Thursday October 15 2015, @02:17PM
For example, without drug patents, there would be little incentive for research.
There is zero credible and rigorous scientific evidence to support that claim, and the burden of proof is on those who wish to create or keep laws.
Meanwhile, patents violate private property rights (can't use your own resources to carry out this set of steps to get this result) and prevent competition from bringing down prices. It might be possible to have governments do the drug research instead of corporate thugs with a profit motive.